A novel derivative of thioridazine shows low toxicity and efficient activity against gram‐positive pathogens by Jørgensen, Nadia S. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
A novel derivative of thioridazine shows low toxicity and efficient activity against gram
positive pathogens
Jørgensen, Nadia S.; Saaby, Lasse; Andersson, Anne M.; Kromann, Sofie; Sheikhsamani,
Ehsan; Permin, Anders; Ronco, Troels; Svenningsen, Søren W.; Christensen, Jørn B.; Olsen,
Rikke H.
Published in:
Antibiotics
DOI:
10.3390/antibiotics9060327
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Jørgensen, N. S., Saaby, L., Andersson, A. M., Kromann, S., Sheikhsamani, E., Permin, A., ... Olsen, R. H.
(2020). A novel derivative of thioridazine shows low toxicity and efficient activity against grampositive pathogens.
Antibiotics, 9(6), [327]. https://doi.org/10.3390/antibiotics9060327
Download date: 10. sep.. 2020
antibiotics
Article
A Novel Derivative of Thioridazine Shows Low
Toxicity and Efficient Activity against
Gram-Positive Pathogens
Nadia S. Jørgensen 1, Lasse Saaby 2, Anne M. Andersson 1, Sofie Kromann 1, Ehsan Sheikhsamani 3,
Anders Permin 4, Troels Ronco 1, Søren W. Svenningsen 5, Jørn B. Christensen 5 and
Rikke H. Olsen 1,*
1 Department of Veterinary and Animal Sciences, University of Copenhagen, Stigboejlen 4,
1870 Frederiksberg C, Denmark; dst742@alumni.ku.dk (N.S.J.); annemarlenealexandra@gmail.com (A.M.A.);
sok@sund.ku.dk (S.K.); troelsronco@gmail.com (T.R.)
2 Bioneer:FARMA, Department of Pharmacy, Universitetsparken 2, 2100 Copenhagen, Denmark;
lasse.saaby@sund.ku.dk
3 Department of animal science, Ferdowsi University, Mashhad IR-91779, Iran; e_sh_s@yahoo.com
4 Unibrains, Kollelevbakken 33, 2830 Virum, Denmark; aper@unibrains.dk
5 Department of Chemistry, University of Copenhagen, Thorvaldsensvej 40, 1871 Frederiksberg C, Denmark;
swsvenningsen@hotmail.com (S.W.S.); jbc@chem.ku.dk (J.B.C.)
* Correspondence: cava@sund.ku.dk
Received: 6 May 2020; Accepted: 13 June 2020; Published: 15 June 2020


Abstract: Thioridazine hydrochloride (HCl) has been suggested as a promising antimicrobial helper
compound for the treatment of infections with antimicrobial-resistant bacteria. Unfortunately, the
therapeutic concentration of thioridazine HCl is generally higher than what can be tolerated clinically,
in part due to its toxic side effects on the central nervous system. Therefore, we aimed to synthesize
a less toxic thioridazine derivative that would still retain its properties as a helper compound.
This resulted in a compound designated 1-methyl-2-(2-(2-(methylthio)-10H-phenothiazin-10-yl)ethyl)-
1-pentylpiperidin-1-ium bromide (abbreviated T5), which exhibited low blood–brain barrier
permeability. The lowest minimal inhibitory concentration (MIC) against Staphylococcus aureus
exposed to the novel compound was reduced 32-fold compared to thioridazine HCl (from 32 µg/mL
to 1 µg/mL). The MIC values for T5 against five Gram-positive pathogens ranged from 1 µg/mL to
8 µg/mL. In contrast to thioridazine HCl, T5 does not act synergistically with oxacillin. In silico
predictive structure analysis of T5 suggests that an acceptably low toxicity and lack of induced
cytotoxicity was demonstrated by a lactate dehydrogenase assay. Conclusively, T5 is suggested as
a novel antimicrobial agent against Gram-positive bacteria. However, future pharmacokinetic and
pharmacodynamic studies are needed to clarify the clinical potential of this novel discovery.
Keywords: thioridazine; novel antimicrobial compound; Gram-positive pathogens
1. Introduction
Antibiotic-resistant bacteria are emerging and constitute a considerable public health issue
worldwide. Since important Gram-positive and Gram-negative human and veterinary pathogens
increasingly become susceptible to a wide range of antibiotics, the clinical need for new treatment
compounds is urgent [1,2]. Regrettably, the pipeline for novel antimicrobials seems to have almost dried
out, and the number of novel antimicrobial agents available on the market has decreased considerably
in the last decades [2–4]. For the same reason, attention has been given to compounds that could
“re-sensitize” antibiotic resistant bacteria to the currently available antibiotics [5–7]. Phenothiazines, a
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group of neuroactive compounds, have been intensively studied as antimicrobial helper compounds,
and have been documented to re-sensitize methicillin-resistant Staphylococcus aureus (MRSA) to oxacillin
in vitro [8,9]. Unfortunately, the promising results produced in vitro have proven difficult to reproduce
in vivo [10,11]. This is most likely due to the toxic side effects of phenothiazines in the needed
concentrations to obtain synergy. At least one study has reported that the animal experiment had
to be terminated prematurely, due to severe behavioral side effects in the phenothiazine-treated
animals [10,11]. We have hypothesized that part of the toxicity of phenothiazines is due to the
compounds adverse effects on the brain, as they readily pass the blood–brain barrier (BBB) [12].
Therefore, the aim of this study was to chemically modify thioridazine hydrochloride (HCl) to generate
a thioridazine derivative that would not pass the BBB, but retain its properties as an antimicrobial
helper compound.
2. Results
2.1. Structure, Yield, and Chemical Characteristics of T5
The product yield of the compound was 0.44g (51%), with the following characteristics: 1H NMR
(500 MHz, CD3OD: δ 7.26 (t, J = 7.1 Hz, 1H), 7.23–7.17 (m, 1H), 7.15–7.06 (m, 2H), 7.04–6.98 (m, 1H),
6.97–6.94 (m, 1H), 6.91 (d, J = 7.3 Hz, 1H), 4.22 (d, J = 13.4 Hz, 1H), 4.10–3.95 (m, 1H), 3.59–3.32 (m, 3H),
3.26 (td, J = 12.9, 3.0 Hz, 1H), 3.06 (tt, J = 10.6, 7.5 Hz, 2H), 2.92 (s, 2H), 2.80 (s, 1H), 2.60–2.52 (m, 1H),
2.49 (s, 3H), 2.01–1.69 (m, 6H), 1.63–1.43 (m, 2H), 1.43–1.14 (m, 4H), 1.08–0.94 (m, 2H), 0.94–0.83 (m, 3H);
and 13C-NMR (126 MHz, CD3OD) δ 146.85, 146.08, 140.45, 140.36, 129.01, 128.97, 128.78, 128.70, 127.68,
124.60, 123.95, 122.20, 117.82, 117.68, 115.64, 115.52, 68.50, 65.80, 63.05, 61.79, 50.30, 44.78, 43.91, 42.63,
29.60, 29.52, 26.37, 26.17, 25.96, 23.37, 23.15, 22.79, 22.11, 21.99, 21.04, 21.01, 15.90, 15.86, 14.29, 14.21.
The found yield of HRMS (MALDI-TOF, dithranol, methanol) [C26H37N2S2] + was 441.2386
(calculated.: 441.2393). The synthesis of T5 is shown in Scheme 1.
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Generally, the results show that T5 has limited cellular permeability and does not impact the 
monolayer integrity or induce cytotoxicity. The apical-to-basolateral transport (flux) across IPEC-J2 
MDR1 cells was markedly higher for thioridazine HCl compared to T5, as shown in the permeability 
and flux curves (Figure 1). 
Scheme 1. Synthesis of 1-methyl-2-(2-(2-(methylthio)-10H-phenothiazin-10-yl)ethyl)-1-pentylpiperidin-1-ium
bromide (T5) from thioridazine HCl.
T5 has two stereocenters, and therefore, it is a mixture of four isomers (two diastereomers and
two enantiomers), which is the reason for the many signals in the 1H NMR and 13C-NMR spectra.
The two en ntiom rs of thioridazine (2S and 2R) have previously been prepared by classical resolution
of the racemat [13] by chiral HPLC [14,15]. Since previous work on the antimicrobi l effect of the
enantiomers of thio idazine did n t s ow any significant diff rence between the two enantiomers,
it was de ided to test the mixture of isomers [16].
2.2. Cellular Permeability and Cytotoxicity of T5
Generally, the results show that T5 has limited cellular permeability and does not impact the
monolayer integrity or induce cytotoxicity. The apical-to-basolateral transport (flux) across IPEC-J2
MDR1 cells was markedly higher for thioridazine HCl compared to T5, as shown in the permeability
and flux curves (Figure 1).
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Figure 1. Basolateral transport assay. The figure shows apical-to-basolateral transport across IPEC-J2 
MDR1 cells for thioridazine HCl and T5. (A) Calculated apparent permeability (Papp); (B) transport 
across the cell monolayer over time. Values on the y-axis represent the amount of either thioridazine 
HCl or T5 appearing in the basolateral chamber at time points indicated on the x-axis. In both graphs, 
the y-axis has been bracketed to better visualize the results for T5. 
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(at 492 nm) on the y-axis as a measure for the lactate dehydrogenase (LDH) release from IPEC-J2 
MDR1 cells exposed to thioridazine HCl and T5. Hank’s balanced salt solution (HBSS) was used as 
negative control, and cell lysate from IPEC-J2 MDR1 cell monolayers treated with ultrapure water 
was used as a positive control. The error bars indicate standard deviations of the mean values. 
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2.3. Antimicrobial Activity of T5
These test results showed that T5 exhibited efficient activity against Gram-positive bacteria in
the absence of human serum. The MIC value for eight different strains ranged from 1–128 µg/mL
(Table 1). In all cases, the minimal bactericidal concentration (MBC) value was equal to the MIC value.
Gram-negative strains (Escherichia coli and Proteus vulgaris) had MIC values at least four-fold higher
than the highest MIC value observed for the Gram-positive strains. The addition of 20% serum to the
assay increased the MIC and MBC at least eight-fold (Table 1).
Table 1. Antimicrobial activity of T5.
Species Strain Origin
MIC (µg/mL)
MBC
(µg/mL)
Br t
MH Broth + 20%
Human Serum
Staphylococcus
aureus JE2 (USA300)
Human clinical
isolate 2 16 2
Staphylococcus
aureus
TCC
BAA-1556
Human clinical
isolate 2 32 2
Staphylococcus
aureus CC398
Veterinary
clinical isolate 1 16 1
Enterococcus
faecalis 72B6
Veterinary
clinical isolate 4 ND 4
Enterococcus
faecium ATCC 700221
Human clinical
isolate 8 ND 8
Proteus vulgaris 4663 Veterinaryclinical isolate 64 ND 64
Escherichia coli E2 Human clinicalisolate ND 64
Escherichia coli APEC O2 Veterinaryclinical isolate 32 ND 32
The table shows the minimal inhibitory concentration (MIC) with and without serum-added Müller–Hinton (MH)
broth and minimal bacterial concentration (MBC) for T5. Five Gram-positive and three Gram-negative clinical
isolates were tested. ND: not determined.
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Viability studies showed that a concentration of T5 at 8 µg/mL was sufficient to completely
eliminate 106 colony forming units (CFU) of S. aureus JE2 within eight hours, while 4 µg/mL reduced
the bacterial concentration 100-fold in the same time period (Figure 3). The checkerboard assay
revealed synergy between thioridazine HCl and oxacillin, which had the lowest FIC index (0.375) with
the oxacillin concentration at 16 µg/mL (reduced from 128 µg/mL) and in the presence of 8 µg/mL
thioridazine HCl (reduced from 32 µg/mL). The lowest FIC index when T5 was combined with oxacillin
was 1; hence, there was no indication of synergy between the two compounds
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Figure 3. Growth and viability curves for S. aureus JE2. The figure shows growth and viability 
curves for S. aureus JE2 exposed to 0, 1, 2, 4, or 8 µg/mL of T5. The bacterial concentration (colony 
forming units (CFU)/ml) is shown on the log-transformed y-axis, and was determined at seven 
different timepoints during an eight-hour period. The experiment was repeated three times, and 
variations in the mean numbers of CFU/ml is indicated by the error bars. 
2.4. In Silico Analysis of T5 
The in silico predictions showed that T5 has a strong affinity for plasma proteins, but is not very 
likely to pass the BBB (Table 2). Moreover, T5 was predicted to be a non-mutagenic (Ames test) and 
non-carcinogenic compound that would be relatively easily absorbed intestinally and orally (Caco-2 
cell permeability). However, a medium risk of blocking the human ether-a-go-go-related gene 
(hERG) potassium channel was found, which could indicate that T5 holds cardiotoxic properties. 
Compared to T5, thioridazine is more toxic regarding mutagenicity, carcinogenicity, and inhibition 
of hERG channels. Values regarding skin permeability, Caco-2 cell permeability, BBB penetration, 
and human intestinal absorption were in the same range for T5 and thioridazine. However, the data 
show that thioridazine has a lower affinity for plasma proteins than T5 (Table 2) 
Table 2. In silico predictions of T5 and thioridazine HCl. 
Feature T5 Thioridazine 
HCl 
Range 
Plasma protein binding (%) 
90.9 
 
62.5 
>90%: chemicals strongly 
bound 
Blood brain barrier penetration 
(Cbrain/Cblood) 
0.1 0.5 
2.0–0.1: middle absorption to 
CNS 
Skin permeability 
(logKp, cm/hour) 
−1.92 −3.7 Not defined 
Caco-2 cell permeability 21.78 31.9 4–70: middle permeability 
Human intestinal absorption (%) 98.26 94.4 
70–100%: well-absorbed 
compounds 
Ames test (TA100) Negative Positive - 
Carcinogenicity Negative Positive - 
hERG inhibition 
Medium 
risk 
High risk - 
The table shows important pharmacokinetic and pharmacodynamic parameters for T5 and 
thioridazine HCl predicted by the web-based application PreADMET. 
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2.4. In Silico Analysis of T5
The in silico predictions showed that T5 has a strong affinity for plasma proteins, but is not very
likely to pass the BBB (Table 2). Moreover, T5 was predicted to be a non-mutagenic (Ames test) and
non-carcinogenic compound that would be relatively easily absorbed intestinally and orally (Caco-2
cell permeability). However, a medium risk of blocking the human ether-a-go-go-related gene (hERG)
potassium channel was found, which could indicate that T5 holds cardiotoxic properties. Compared to
T5, thioridazine is more toxic regarding mutagenicity, carcinogenicity, and inhibition of hERG channels.
Values regarding skin permeability, Caco-2 cell permeability, BBB penetration, and human intestinal
absorption were in the same range for T5 and thioridazine. However, the data show that thioridazine
has a lower affinity for plasma proteins than T5 (Table 2)
Table 2. In silico predictions of T5 and thioridazine HCl.
Feature T5 Thioridazine HCl Range
Plasma protein binding (%) 90.9 62.5 >90%: chemicals stronglybound
Blood brain barrier penetration
(Cbrain/Cblood)
0.1 0.5 2.0–0.1: middle absorption toCNS
Skin permeability
(logKp, cm/hour) −1.92 −3.7 Not defined
Caco-2 cell permeability 21.78 31.9 4–70: middle permeability
Human intestinal absorption (%) 98.26 94.4 70–100%: well-absorbedcompounds
Ames test (TA100) Negative Positive -
Carcinogenicity Negative Positive -
hERG inhibition Medium risk High risk -
The table shows important pharmacokinetic and pharmacodynamic parameters for T5 and thioridazine HCl
predicted by the web-based application PreADMET.
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3. Discussion
The main motivation for synthesizing T5 was to obtain a less toxic thioridazine derivate that
would not pass the BBB, yet would retain a synergistic effect with oxacillin. While we have shown that
transport of T5 across monolayers of IPEC-J2 MDR1 cells was reduced by more than 100-fold compared
to thioridazine HCl (Figure 1), T5 did not display synergy with oxacillin. The lack of synergy differs
from the “mother” compound, which therefore could indicate a different mode of action regarding
bacterial interaction. Surprisingly, the antimicrobial activity had been significantly improved for T5
compared to thioridazine HCl, at least for the Gram-positive bacterial species (Table 1). The MIC
values for T5 against three MRSA strains ranged from 1–2 µg/mL (Table 1), whereas previous studies
have shown that MIC values for thioridazine against MRSA strains range from 20–32 µg/mL [8,9,17].
In comparison, previous studies using a similar broth microdilution method as in this study found
MIC values ranging from 0.5–1.0 µg/mL when three MRSA strains (including JE2) were tested against
vancomycin, which is considered effective against MRSA [18–20]. Furthermore, a previous study [18]
found MIC values from 0.5–2.0 µg/mL for an Enterococcus faecium and an Enterococcus faecalis strain
when tested against vancomycin, whereas the MIC values for these species ranged from 4–8 µg/mL
in the present study (Table 1). In contrast, the activity of T5 against Gram-negative E. coli strains
(MIC: 32–64 µg/mL) was not remarkably improved compared to a previous study of thioridazine
against E. coli (MIC: 128 µg/mL) [17]. In comparison, a previous study performed in accordance to
CLSI’s guidelines [21] found that the majority of the E. coli isolates (74/85) had a MIC value ranging
from 1–8 µg/mL, and EUCAST [22] has determined the MIC breakpoint for Enterobacterales to be
8 µg/mL in 2020, when tested against the commonly used antibiotic ampicillin. Since T5 has exhibited
low activity against Gram-negative bacteria, it could indicate that the improved activity of T5 is
due to interactions with the Gram-positive cell wall. It cannot, however, be excluded that T5 is
interacting with intracellular bacterial compounds and is only permeable to the Gram-positive cell
wall. For thioridazine HCl, it has been proposed that its antimicrobial effect is at least partly due to
the compound disturbing the peptidoglycan biosynthesis at a stage that precedes transpeptidation
by penicillin-binding proteins [23,24]. This supports observation of the re-sensitizing properties of
thioridazine when applied to oxacillin-resistant bacteria. Since T5 does not act synergistically with
oxacillin, it most likely has a different mode of antimicrobial action than thioridazine HCl. It could be
speculated whether the thioridazine part of T5 is still able to interfere with membrane-related processes,
whereas the positively charged sidechain (Scheme 1) would add to the complete disintegration
of the membrane, thereby causing lysis of the bacterial cell. Furthermore, the strong bactericidal
effect of T5 supports the hypothesis of interference with membrane-related process modes of action.
Like thioridazine HCl, T5 is bactericidal by the definition that its MIC and MBC values do not differ
more than four-fold [25] (Table 1); furthermore, 4 × MIC is sufficient to eliminate 106 CFU in less than
8 h (Figure 3). In addition, phenothiazines, including thioridazine, have been reported to act as efflux
pump inhibiters [9,26]. Since efflux pumps are essential in biofilm formation [26,27], it should be further
investigated whether T5 interacts with efflux pumps and possesses biofilm inhibitory properties.
For an antimicrobial intended to treat sepsis, it is critical that an appropriate plasma concentration
of the compound can be achieved. The plasma concentration of a compound depends on various factors,
such as elimination rate and plasma protein binding (PPB) versus free fraction of the compound [28].
In general, PPB reduces the free fraction of a drug available for bacterial interaction, since only the
unbound antibiotic is pharmacologically active. For T5, a high degree of plasma protein binding (90%)
was predicted in silico (Table 2). This predication was supported by a significant increase in MIC
when 20% human serum was included in the MIC assay (Table 1). High PPB of an antimicrobial does
not exclude it from having therapeutic potential, as e.g., ceftriaxone (PPB: 90–95%) and fusidic acid
(PPB: approximately 98%) that exhibit high PPB values, yet are highly appreciated antibiotics [28,29].
In such cases, the pharmacokinetics and pharmacodynamics of the compound have to be carefully
considered [29]. In contrast to T5, thioridazine was predicted to exhibit a much weaker affinity for
plasma proteins (Table 2). This means that a higher fraction of thioridazine molecules are free to
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cross the BBB and affect the CNS, which could be one of the reasons why severe side effects have
been reported previously in phenothiazine-treated animals [10,11]. The PreADMET web application
predicts a medium permeability of T5 in Caco-2 cells, and the compound is thus predicted to be
well-absorbed after oral administration. This finding must, however, be interpreted with caution. T5 is
a constantly charged molecule, and this feature is often unfavorable for passing biological cell linings,
which is confirmed by the lack of passage through monolayers of IPEC-J2 hMDR1 cells (Figure 1).
Therefore, it is likely that passage over the intestinal lining will be lower than predicted, and in silico
and in vitro studies must be applied to confirm whether T5 can actually pass the epithelium lining of
the intestine [30].
For non-septic applications, e.g., the topical treatment of infected wounds, PPB would not be
relevant. Here, it is of greater importance that the compound is not skin-irritating, and does not
penetrate the vascularized dermis of the skin, with a risk of systemic exposure spread rather than
having a local effect. Based on the in silico prediction of skin permeability (Table 2), T5 could represent
a potential candidate for a topical antimicrobial treatment.
For any medical compound, an assessment of the toxicological profile is essential. Mutagenicity and
carcinogenicity were both predicated to be negative for T5. However, medium risk for human
ether-a-go-go-related gene (hERG) potassium channel inhibition was predicted. hERG plays an
important role in the repolarization of cardiac action potential. It is a serious challenge for a medical
compound to reach the market if it has been documented that the compound mediates cardiotoxicity [31].
In fact, cardiotoxicity was one of the primary reasons why thioridazine HCl was withdrawn from the
market [29]. A recent study, however, has shown that it is only the (+) enantiomer of thioridazine
that processes its cardiotoxic properties, whereas the (+) and (−) enantiomers of thioridazine possess
similar antimicrobial activities [32]. Hence, if further in vitro and in vivo studies may confirm the
cardiotoxicity of T5, the toxicity could be considerably reduced using only the (−) enantiomer of
thioridazine HCl for synthesis of T5.
4. Materials and Methods
4.1. Synthesis of T5 (1-methyl-2-(2-(2-(methylthio)-10H-phenothiazin-10-yl)ethyl)-1-pentylpiperidin-1-umbromide)
The present design was chosen in order to avoid transport over the–brain barrier by converting
thioridazine HCl into a permanently charged derivative. A stirred mixture of thioridazine (0.62 g;
1.67 mmol), 1-bromopentane (2.0 mL; 16 mmol), and acetonitrile (18 mL) was refluxed overnight
under an N2 atmosphere. After cooling to room temperature, the mixture was added with stirring to
diethyl ether (200 mL), causing the product to precipitate. The product was isolated by filtration and
dried in a vacuum. The yield was 0.44 g (51%). NMR spectra were recorded on a Bruker 500 MHz
instrument equipped with a cryoprobe. HRMS was recorded on a Bruker Solarix XR ESI-MALDI
FT-MS. All chemicals were obtained from commercial suppliers, and were used as received.
4.2. Transport Assay
At present, a well-characterized cell model resembling the human blood–brain barrier does
not currently exist. However, according Di et al. [33], in vitro cellular permeability data, combined
with estimates of whether drug compounds are recognized and transported by P-glycoprotein, are
predictive for estimating in vivo central nervous system exposure. Therefore, to investigate if the
novel thioridazine derivative would have lower BBB permeability compared to thioridazine HCl,
the apical-to-basolateral transport of the two different compounds across monolayers of IPEC-J2
MDR1 cells, seeded and cultured on Transwell supports, was measured. The IPEC-J2 MDR1 cells
formed electrically tight monolayers and had a high expression of the human efflux transporter
P-glycoprotein [34]. Due to the tight barrier and over-expression of human P-glycoprotein, transport
experiments across monolayers of the IPEC-J2 hMDR1 cells therefore provided cellular permeability
data combined with P-glycoprotein activity.
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For transport experiments, both compounds were dissolved in ultrapure water to a concentration
of 1 mM and further diluted in Hank’s balanced salt solution (HBSS) (Life technologies, Taastrup,
Denmark), supplemented with 0.05% bovine serum albumin (BSA) (Sigma-Aldrich, Brøndby, Denmark)
and buffered with 10 mM HEPES (2-[4-(2-hydroxyethyl) piperazin-1-yl] ethanesulfonic acid; AppliChem
GmbH, Darmstadt, Germany) to a pH value of 7.4. IPEC-J2 cells were seeded onto permeable supports
(T12, Corning cci-3401) and cultured for 15–17 days. The culture medium was changed every other
day in both the apical and basolateral chamber.
On the day of transport, the cells were equilibrated to ambient temperatures, and the transepithelial
electrical resistance (TEER) was measured across the cell monolayers. Subsequently, the cell layers were
washed twice with supplemented HBSS, and the TEER was measured again. The transport experiment
was started by replacing the supplemented HBSS buffer in the apical chamber with HBSS solutions of
the experimental compounds. Over a period of two hours, samples of 100 µL were taken from the
basolateral chamber at t = 15, 30, 45, 60, 90, and 120 min. All samples were stored at −20 ◦C until
analysis by means of HPLC–MS. The transport experiment was tested in triplicate. After the transport
study was stopped, the cell layers were washed twice with HBSS, and the TEER was measured.
To assess possible alterations of the barrier properties of the IPEC-J2 MDR1 cell monolayers, in a
parallel transport experiment, 14C-mannitol (0.5 µCi/mL) was added to the two compound solutions.
The experiment was performed as described above, with the exceptions that the two compounds
were tested in duplicate, and that samples were mixed with 2 mL of Ultima Gold Scintillation Fluid
(PerkinElmer, Boston, MA, United States) and analyzed by liquid scintillation counting.
4.3. Lactate Dehydrogenase Colorimetric Assay
To investigate if T5 induced cytotoxicity in IPEC-J2 MDR1 cells, LDH release from the cell
monolayers was measured in samples of the donor solutions, taken from the apical compartment after
120 min of exposure in IPEC-J2 MDR1 cell monolayers. The cell lysate of cells treated with ultrapure
water was included in the analysis as a positive control. Samples were analyzed in duplicate according
to manufacturer’s protocol (Roche Diagnostics GmbH, Mannheim, Germany). After incubations with
donor solutions (thioridazine HCl or T5) on IPEC-J2 MDR1 cells, absorbance at 492 nm was measured
as a mean for LDH release. Hank’s balanced salt solution (HBSS) was used as negative control, and cell
lysate from IPEC-J2 MDR1 cell monolayers treated with ultrapure water was used as a positive control.
4.4. Antimicrobial Activity
The minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) were
determined for eight bacterial strains of human and veterinary clinical importance (Table 1). All strains
were stored at −80 ◦C in a mixture of one part glycerol (50%) and three parts Brain Heart Infusion
media (Sigma, Copenhagen, Denmark) until use. The strains were plated on agar plates (Oxoid
blood agar base; Oxoid, Roskilde, Denmark) supplemented with 5% bovine blood, and incubated in
an appropriate atmosphere (either aerobically or anaerobic). MIC was determined based on CLSI’s
guidelines. Briefly, the broth microdilution method was used to determine the MIC. To obtain the
desired concentration range (0–256 µg/mL), serial two-fold dilutions of T5 in Müller–Hinton (MH)
broth (Sigma-Aldrich, Brøndby, Denmark) were prepared. For each strain, single colonies grown for
approximately 24 h on a cultured agar plate were picked and suspended in 0.9% NaCl to reach an
optical density equal to that of the 0.5 McFarland standard, using a Sensititre nephelometer (Thermo
Scientific, Roskilde, Denmark). The suspensions were then 100-fold diluted in MH broth, and 100 µL of
bacterial suspension in MH broth were then added individually into each well of a sterile 96-well plate
containing either 100 µL of T5 or the control (pure MH broth), reaching a final inoculum of 5 × 105
colony forming units (CFU). The positive control wells included only MH broth and the bacterial
suspension, whereas the negative control wells included only MH broth and T5. The plates were
incubated at 37 ◦C for approximately 24 h. MIC tests were performed in triplicates on separate days.
The MIC was defined as the lowest drug concentration that completely inhibited visible bacterial
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growth. To establish MBC, 100 µL from each well not containing visual growth were plated on blood
agar plates and incubated at 37 ◦C for approximately 24 h. For each strain, MBC was determined as
the lowest concentration of T5 that had reduced the CFU of the inoculum (5 × 105 CFU/well) by ≥ 99%.
To assess the impact of serum proteins on the activity of T5, the microdilution assays were repeated as
stated above, but replacing 40 µL of the MH broth with 40 µL human serum (Sigma-Aldrich, Brøndby,
Denmark), resulting in a 20% serum concentration in the assay.
4.5. Growth and Viability Assays
Viability assays of S. aureus JE2 in the presence of 0, 1, 2, 4, and 8 µg/mL T5 in MH broth in
eight-hour intervals was performed. MH cultures of S. aureus JE2 in early exponential phase were
transferred to 100 mL flasks, and the various concentrations of T5 was added to each flask. The flasks
were placed in a 37 ◦C water bath with 100 RPM shaking. The number of CFU for each T5 exposure
condition was determined at seven time points during the eight hours. For each time point, 100 µL
culture from each flask was submitted to serial 10-fold dilution in a 0.9% NaCl solution, and 100 µL
from each dilution was plated on an MH agar plate. The plates were incubated for 24 h at 37 ◦C,
and CFU were determined by counting colonies on the plates. The experiment was repeated in
biological triplicates.
4.6. Oxacillin Synergy Assessment
To investigate if T5 is interacting synergistically with oxacillin, a checkerboard assay was performed.
In addition, a checkerboard assay of thioridazine HCl combined with oxacillin was performed as a
control. For each checkerboard assay, a total of 50 µL of MH broth was distributed into each well of
the microdilution plates. A T5 or thioridazine HCl solution was serially diluted along the ordinate,
while the oxacillin was diluted along the abscissa. An inoculum equal to a 0.5 McFarland turbidity
standard was prepared for the MIC/MBC assays. Each microtiter well was inoculated with 100 µL of a
bacterial inoculum at 5 × 105 CFU/mL, and the plates were incubated at 37 ◦C for 24 h under aerobic
conditions, with a final volume of 200 µL. After incubation, a fractioned inhibitory index (ΣFIC) was
calculated for each well without visual recognizable growth. The ΣFICs were calculated as follows:
ΣFIC = FIC A + FIC B, where FIC A is the MIC of thioridazine HCl or T5 in the combination, or the
MIC of thioridazine HCl or T5 alone. FIC B is the MIC of oxacillin in the combination or the MIC of
oxacillin alone. The combination is considered synergistic when the ΣFIC is ≤ 0.5, indifferent when the
ΣFIC is > 0.5 and < 2, and antagonistic when the ΣFIC is ≥ 2.
4.7. In Silico Analysis of Pharmacokinetics and Toxicity
The web-based application PreADMET [35] was used for in silico predicting of T5 characteristics,
including human intestinal absorption, plasma protein binding, caco-2 cell permeability, skin
permeability, mutagenicity, and carcinogenicity. For data input for the PreADMET application, the
SMILES formula of T5 ([Br-].CCCCC[N+]1(C)CCCCC1CCN1C2=CC=CC=C2SC2=CC=C(SC)C=C12)
and thioridazine HCl (C1=4(C(SC=3(C(N1CCC2([N+](CCCC2)C))=CC=CC=3))=CC=C(C=4)SC).[Cl-])
were converted to MOLfiles using Cheminfo.org.
5. Conclusions
Here we have synthesized a thioridazine derivative that exhibits low blood–brain barrier
permeability and highly improved antimicrobial activity, compared to its “mother” compound.
In vitro investigations and in silico predications indicated that T5 could represent a novel antimicrobial
compound for the clinical treatment of infections caused by Gram-positive bacteria. These data strongly
call for further pharmacokinetic and pharmacodynamic studies to fully investigate the therapeutic
potential of T5, as well as a full elucidation of the antimicrobial mode of action. Furthermore, this
study demonstrates that modest chemical modification may induce a compound to change from an
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antipsychotic to an antibiotic. This perhaps opens a new door in the search for novel antimicrobials
that can minimize the global issue regarding emerging multidrug-resistant pathogens.
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